2 withdrawn, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 2, Completed 1 |
Follow Stage IIIC Primary Peritoneal Cancer: new trials by email Literature Review of Stage IIIC Primary Peritoneal Cancer trials Research Report on Stage IIIC Primary Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | Mayo Clinic | 24 | 2012-07-24 | 2024-08-21 |
Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Breast Neoplasms (1)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Fallopian Tube Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Ovarian Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3)
Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Sirolimus (1) · aldesleukin (1) · sargramostim (1)
Barbara Ann Karmanos Cancer Institute (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (2)
Kunle Odunsi (1) · Lawrence Lum (1) · Matthew S. Block, M.D., Ph.D. (1)
P30CA016056 (1), P30CA022453 (1), R01CA158318 (1)